Immunai entered a research collaboration with Boehringer Ingelheim valued at up to $15 million through 2027, using Immunai’s single-cell immune profiling platform to identify novel T-cell targets across oncology and autoimmune disease. The work is designed to collect data from thousands of patient samples, then apply Immunai’s AI-enabled analytics to detect patterns of T-cell dysfunction. In the first phase, the companies will evaluate whether immune profiles can generate starting points for new drug discovery projects at Boehringer Ingelheim. The platform integrates multiomic measurements including single-cell RNA-seq, CITE-seq, ATAQ-seq, proteomics, and spatial transcriptomics. Immunai’s CEO Noam Solomon said the collaboration aims to identify therapeutic opportunities that might be missed by separating cancer immunology and inflammation-focused research. Why it matters: partnerships that connect large clinical immune datasets to target nomination workflows can shorten the path from patient biology to early-stage therapeutic assets.